TuHURA Biosciences Enters Exclusivity and Right of First Offer Agreement for Kineta's (KTRA) KVA12123 Jul 8, 2024 06:31AM
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 Novel anti-VISTA Checkpoint Inhibitor Jul 8, 2024 06:30AM
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor Jul 8, 2024 06:30AM
Kintara Therapeutics (KTRA) is Suspending Development of VAL-08 Oct 31, 2023 08:02AM
Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study Oct 31, 2023 08:00AM
View Older Stories

Oct 11, 2023 08:00AM Kintara Therapeutics to Present at the 8th Annual Dawson James Small Cap Growth Conference
Oct 2, 2023 08:00AM Kintara Therapeutics to Present at the LD Micro Main Event XVI Conference
Sep 25, 2023 07:30AM Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting
Sep 5, 2023 08:00AM Kintara Therapeutics to Present at the 2023 European Association for Neuro-Oncology Annual Meeting
Aug 17, 2023 05:26PM Kintara Therapeutics to Host Virtual KOL Event on VAL-083, A Potential First-in-Class Small Molecule Chemotherapeutic for Glioblastoma, on August 21, 2023
Aug 9, 2023 08:16AM Kintara Therapeutics to Present at the Emerging Growth Conference
Aug 8, 2023 07:00AM Presenting on the Emerging Growth Conference on August 9 & 10 Register Now
Jul 19, 2023 08:00AM Kintara Therapeutics to Participate in the Fifth Annual Glioblastoma Awareness Day in Washington, D.C.
Jun 28, 2023 04:15PM Kintara Therapeutics Awarded $2.0 Million National Institutes of Health SBIR Grant to Support the Clinical Development of REM-001
Jun 16, 2023 08:00AM Kintara Therapeutics to Participate in the Maxim Group Virtual Healthcare Conference
May 19, 2023 08:30AM Kintara Therapeutics to Commemorate National Brain Tumor Awareness Month with Ringing the Bell at Nasdaq Closing Along with Global Coalition for Adaptive Research and the National Brain Tumor Society
May 11, 2023 08:15AM Kintara Therapeutics Announces Fiscal 2023 Third Quarter Financial Results and Provides Corporate Update
May 8, 2023 08:30AM Kintara Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference
May 1, 2023 08:30AM Kintara Therapeutics to Present at the Aegis Capital Virtual Conference
Apr 14, 2023 12:00PM Kintara Therapeutics Announces Data Presentation at the 2023 American Association for Cancer Research Annual Meeting
Mar 15, 2023 08:00AM Kintara Therapeutics to Present Two Posters at the 2023 American Association for Cancer Research Annual Meeting
Mar 10, 2023 08:30AM Kintara Therapeutics Scheduled to Present at Two Conferences the Week of March 13, 2023
Feb 14, 2023 05:00PM Kintara Therapeutics Announces Fiscal 2023 Second Quarter Financial Results and Provides Corporate Update
Jan 30, 2023 08:00AM Kintara Therapeutics to Present at the 2023 BIO CEO & Investor Conference
Jan 9, 2023 08:30AM Kintara Therapeutics to Present at the Biotech Showcase Conference on January 10, 2023
Dec 15, 2022 08:09AM Kintara Therapeutics (KTRA) Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma
Dec 15, 2022 08:00AM Kintara Therapeutics Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)
Dec 1, 2022 08:00AM Kintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022
Nov 30, 2022 08:08AM Kintara Therapeutics (KTRA) Regains Compliance with Nasdaq Minimum Bid Price Requirement
Nov 30, 2022 08:00AM Kintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Nov 28, 2022 08:02AM Kintara Therapeutics (KTRA) Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic Breast Cancer
Nov 28, 2022 08:00AM Kintara Therapeutics Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic Breast Cancer
Nov 18, 2022 08:00AM Kintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual Meeting
Nov 11, 2022 08:00AM Kintara Therapeutics (KTRA) Announces 1-for-50 Reverse Stock Split
Nov 11, 2022 08:00AM Kintara Announces One-for-Fifty Reverse Stock Split
Nov 9, 2022 05:20PM Kintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate Update
Oct 19, 2022 08:15AM Kintara Therapeutics (KTRA) Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study
Oct 19, 2022 08:15AM Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study
Sep 27, 2022 08:15AM Kintara Therapeutics Announces Fiscal 2022 Financial Results and Provides Corporate Update
Sep 8, 2022 07:00AM Kintara Therapeutics Announces Three Abstracts Have Been Accepted for the 2022 Society for Neuro-Oncology Annual Meeting
Aug 9, 2022 09:01AM Kintara Therapeutics (KTRA) Approved to Proceed with REM-001 Study
Aug 9, 2022 09:00AM Kintara Therapeutics Receives Study May Proceed Letter from the FDA for REM-001 for Cutaneous Metastatic Breast Cancer
Jun 21, 2022 08:00AM Kintara Therapeutics to Present at the Alliance Global Partners Summer Healthcare Conference
Jun 15, 2022 09:03AM Kintara Therapeutics (KTRA) Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed Glioblastoma
Jun 15, 2022 09:00AM Kintara Therapeutics Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed Glioblastoma
Jun 10, 2022 09:00AM Kintara Therapeutics to Present at the JMP Securities Life Sciences Conference
Jun 3, 2022 09:01AM Kintara Therapeutics (KTRA) Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement
Jun 3, 2022 09:00AM Kintara Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement
May 27, 2022 09:30AM Kintara Announces First European Site Activation in Switzerland in GCAR Phase 2/3 Clinical Trial for Glioblastoma
May 13, 2022 08:00AM Kintara Therapeutics Announces Fiscal 2022 Third Quarter Financial Results and Provides Corporate Update
Apr 26, 2022 07:30AM Kintara Therapeutics to Present at the Planet MicroCap Showcase 2022
Apr 14, 2022 04:05PM Kintara Announces Closing of $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Apr 12, 2022 08:31AM Kintara Therapeutics (KTRA) Prices 16.23M Share Offering at $0.53/sh
Apr 12, 2022 08:30AM Kintara Announces $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Apr 11, 2022 02:32PM Kintara Therapeutics (KTRA) Presents Additional VAL-083 Data
View Older Stories